​

1. Stereo- and Enantioselective Synthesis of sp3-rich Molecules: Breaking the symmetry/Desymetrization is one of the powerful tool to access enantio-enriched molecules. In our group, we explore stereoselective desymmetrization of prochiral symmetrical cyclohexa-2,5-dienones to straightforward synthesis of sp3-rich polycyclic compounds and heterocycles. 

2. Synthesis of Multi-functional High-valued Aromatics though NGP: Multi-component reactions that enables in forging multiple bonds in highly controllable manners provides an efficient strategy in chemical synthesis. We explored the reactivity to access site-selective multi-functional arenes through neighboring group participation (NGP) strategy.​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

3. Strategy Development for Novel Boron Heterocycles and chiral Boron: Along with the conventional use of boron in organometallic/synthetic transformation, recently boron heterocycles attracted much attention in medicinal and material chemistry. We are working on development of strategy for the synthesis of novel boron-containing heterocycles. Unlike, much explored in the central or axial chirality on carbon center, we have an interest on construction of boron-stereogenic compounds.

​

•                        Chem. Comm. 2021, 57, 97083.

​

Medicinal Chemistry: Our team is also actively involved in exploration of in-house generated molecular library in different therapeutics/medicinal chemistry. Development of multidrug resistance in pathogens is threatening to public health. In such case, development of new molecular candidates with new mode of action could be a probable solution to this.

​

• Exploration of novel boron candidates: Despite the fact of favorable pharmaceutical features associated with boron, very little is currently explored in therapeutics, unlike ‘deuterium click’. By introducing tri-coordinated boron in the drug molecule and exploiting its Lewis acidic character with therapeutic target could alter the mode of action/efficacy. After finding the place of boron-based drug molecule, Velcade® in the market and many more in pipe lines, it provides an avenue to medicinal chemists to explore in this area. It may provide high IP values and improved therapeutic properties. Our group venture in development of synthetic strategy for the generation of novel boron-based heterocycles and exploration of their therapeutic potential.

• We are working on different therapeutic areas; CNS (selective GPCR modulators) and AMR etc.

​